RN
Rangraj Niranjanbhai Brahmbhatt
About Rangraj Niranjanbhai Brahmbhatt
Data last updated:
Rangraj Niranjanbhai Brahmbhatt has 11 years in corporate governance. Holds Director role. Currently with 1 company, including Trims Pharma Private Limited. Engaged in General Business. Contributes to corporate operations. The largest current company by reported revenue is Trims Pharma Private Limited at ₹0.03 Cr (FY 2021).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Trims Pharma Private Limited U24100GJ2015PTC082673 | Director | 24 Mar 2015 | 2015 | ₹0.03 Cr (FY 2021) | Active |
Previous companies
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Rangraj Niranjanbhai Brahmbhatt
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rangraj Niranjanbhai Brahmbhatt
Rangraj Niranjanbhai Brahmbhatt has 11 years in corporate governance. Holds Director role. Currently with 1 company, including Trims Pharma Private Limited. Engaged in General Business. Contributes to corporate operations. The largest current company by reported revenue is Trims Pharma Private Limited at ₹0.03 Cr (FY 2021).
Rangraj Niranjanbhai Brahmbhatt is associated with 1 company as Director, including Trims Pharma Private Limited (₹0.03 Cr).
Rangraj Niranjanbhai Brahmbhatt has expertise in General Business.
Rangraj Niranjanbhai Brahmbhatt has 11 years in corporate governance.
By reported revenue, the largest current company of Rangraj Niranjanbhai Brahmbhatt is Trims Pharma Private Limited, with revenue of ₹0.03 Cr (FY 2021).
Rangraj Niranjanbhai Brahmbhatt currently holds positions at 1 company: Trims Pharma Private Limited (₹0.03 Cr).